Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM Trial
Question
Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM Trial
Direct answer
Regulatory clearance for clinical testing in Germany derisks AVR clinical development milestones, improving terminal valuation multiples. — bullish pressure on AVR via regulatory approval derisking clinical pipeline progression.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-20
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM Trial”, revision 1, evidence through 2026-10-20. https://marketontology.com/catalysts/2026-10-20/anteris-secures-german-bfarm-regulatory-clearance-for-duravr-paradigm-trial-6bdd67
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| AVR | ▲Bull | 1–4 weeks | regulatory approval derisking clinical pipeline progression | 83 |
Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM Trial
Regulatory clearance for clinical testing in Germany derisks AVR clinical development milestones, improving terminal valuation multiples. — bullish pressure on AVR via regulatory approval derisking clinical pipeline progression.
Anteris Technologies received BfArM regulatory clearance to initiate PARADIGM trial for DurAVR in Germany
- SourceAnteris Technologies received BfArM regulatory clearance to initiate PARADIGM trial for DurAVR in Germany
- TransmissionRegulatory clearance for clinical testing in Germany derisks AVR clinical development milestones, improving terminal valuation multiples.
- SummaryAnteris Technologies received regulatory clearance from German authority BfArM for its PARADIGM trial. The decision enables German trial sites to recruit severe aortic stenosis patients for the DurAVR heart valve.
- AVRDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AVR closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AVR price vs. pre-event level
- AVR volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.